Israel approved a plan to invest 1 billion shekels ($275 million) to digitize the personal health records of its nearly 9 million citizens to help develop new drugs.
AbbVies stock $ABBV is getting hammered this morning after its $10 billion Rova-T program posted poor mid-stage results for third-line small cell lung cancer, forcing the company to scuttle any plans to seek an accelerated approval for the closely-watched drug after talks with skeptical regulators.
Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA Priority Review designation; provides clinicians with pediatric-specific safety and clinical data Novartis continues commitment to people living with CML, including pediatric patients with this cancer
SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners.
Medical device design agency, Team Consulting, has created the Convesaid haemostat spray device that stops bleeds during surgery.
Eli Lilly’s one-time blockbuster hopeful baricitinib $LLY is back and on track and ready to run a gamut of outside experts at the FDA.
TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.
Researchers have developed what they have dubbed a ‘brain stethoscope’, a device capable of turning EEG brain wave data into sound. The device is able to detect epileptic seizures that do not result in convulsions.
Patient engagement platform Medical Mindset just landed $1 million in investment capital. The company's platform allows patients to build a HIPAA-compliant health profile, which they can use to check into an appointment by swiping their smartphone.
GlaxoSmithKline's new CEO Emma Walmsley isn’t the only one shaking things up at the top of the British drugmaker.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.